Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"iVeena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iVeena Announces Positive Topline Results; IVMED-80 Advancing to Phase 3 Clinical Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"iVeena","sponsor":"Glaukos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.0 million","newsHeadline":"Glaukos Licenses Iveena\u2019s Investigational Keratoconus Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"iVeena Awarded NEI-SBIR Grant for Progressive Myopia Drug Candidate IVMED-85","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by iVeena

    Menu

    iVeena

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              iVeena

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iVeena Awarded NEI-SBIR Grant for Progressive Myopia Drug Candidate IVMED-85

              Details:

              The grant will be used for the development of IVMED-85, an investigational eyedrop formulation containing copper intended for treatment of pediatric myopia. IVMED-85 will be the first eye drop inducing both scleral and corneal crosslinking for myopia control.

              Lead Product(s): IVMED-85

              Therapeutic Area: Ophthalmology Product Name: IVMED-85

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Eye Institute

              Deal Size: $0.3 million Upfront Cash: Undisclosed

              Deal Type: Funding October 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iVeena

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glaukos Licenses Iveena’s Investigational Keratoconus Therapy

              Details:

              Under the licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 (copper sulfate), a pharmacologic treatment for keratoconus.

              Lead Product(s): Copper Sulphate Pentahydrate

              Therapeutic Area: Ophthalmology Product Name: IVMED-80

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Glaukos

              Deal Size: Undisclosed Upfront Cash: $10.0 million

              Deal Type: Licensing Agreement August 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iVeena

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iVeena Announces Positive Topline Results; IVMED-80 Advancing to Phase 3 Clinical Trials

              Details:

              IVMED-80 is a proprietary non-surgical, non-invasive, disease modifying intervention with FDA orphan designation that upregulates lysyl oxidase (LOX) and induces corneal crosslinking pharmacologically.

              Lead Product(s): IVMED-80

              Therapeutic Area: Ophthalmology Product Name: IVMED-80

              Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iVeena

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development

              Details:

              These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric high myopia and adult low myopia.

              Lead Product(s): IVMED-80

              Therapeutic Area: Ophthalmology Product Name: IVMED-80

              Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: National Eye Institute

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Series B Financing August 25, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY